Bioage Labs, INC. (BIOA) — SEC Filings

Q: What are the key financial highlights for Bioage Labs, INC.?

Key financial highlights for Bioage Labs, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Bioage Labs, INC.?

Key executives at Bioage Labs, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Bioage Labs, INC. stock?

Risk factors for Bioage Labs, INC. (BIOA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Bioage Labs, INC.?

Forward-looking statements and predictions from Bioage Labs, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Bioage Labs, INC.. Recent 144 filing on Apr 1, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Bioage Labs, INC. on SEC EDGAR

Overview

Bioage Labs, INC. (BIOA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 144 filed on Apr 1, 2026: On April 1, 2026, BioAge Labs, Inc. filed a Form 144, indicating a proposed sale of securities. The filing lists a mailing address for the company at 1445A South 50th Street, Richmond, CA 94804, and a business address at 5885 Hollis Street, Suite 370, Emeryville, CA 94608. Paul D. Rubin is listed as

Sentiment Summary

Across 21 filings, the sentiment breakdown is: 18 neutral, 3 mixed. The dominant filing sentiment for Bioage Labs, INC. is neutral.

Filing Type Overview

Bioage Labs, INC. (BIOA) has filed 1 144, 2 10-K, 5 8-K, 4 10-Q, 1 DEF 14A, 3 SC 13G, 2 SC 13D, 2 S-1/A, 1 S-1 with the SEC between Sep 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (21)

BioAge Labs Files Form 144 for Security Sale — 144 · Apr 1, 2026 Risk: medium
On April 1, 2026, BioAge Labs, Inc. filed a Form 144, indicating a proposed sale of securities. The filing lists a mailing address for the company at 1445A Sout
BioAge's BGE-102 Shows Strong CV Risk Reduction in Phase 1 Data — 10-K · Mar 24, 2026 Risk: high
BioAge Labs, Inc. (BIOA) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases by targeting human aging biology.
BioAge Labs Files 8-K on Financial Results & Reg FD Disclosure — 8-K · Mar 24, 2026
BioAge Labs, Inc. filed an 8-K on March 24, 2026, reporting on its results of operations and financial condition under Item 2.02, and making Regulation FD discl
BioAge Labs Files 8-K Report — 8-K · Dec 4, 2025 Risk: low
On December 4, 2025, BioAge Labs, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and
BioAge Narrows Quarterly Loss, Boosts Revenue Amid R&D Spend — 10-Q · Nov 6, 2025 Risk: high
BioAge Labs, Inc. reported a net loss of $20.17 million for the three months ended September 30, 2025, an improvement from a net loss of $23.41 million in the s
BioAge Labs Reports No Revenue, Leans on Novartis Collaboration — 10-Q · Aug 6, 2025 Risk: high
BioAge Labs, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the
BioAge Labs Files 8-K on Shareholder Votes — 8-K · Jun 9, 2025 Risk: low
BioAge Labs, Inc. filed an 8-K on June 9, 2025, reporting on matters submitted to a vote of security holders as of June 5, 2025. The filing details the company'
BioAge Labs Files 8-K Report — 8-K · Jun 4, 2025 Risk: low
On June 4, 2025, BioAge Labs, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding tra
BioAge Labs Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
BioAge Labs, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial instruments mentioned incl
BioAge Labs Sets 2025 Shareholder Meeting — DEF 14A · Apr 17, 2025 Risk: low
BioAge Labs, Inc. filed its definitive proxy statement on April 17, 2025, for its 2025 Annual Meeting of Stockholders. The meeting will be held on June 5, 2025.
10-K Filing — 10-K · Mar 20, 2025
SC 13G Filing — SC 13G · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 12, 2024
BioAge Labs Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
BioAge Labs, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial activities and includes information related to its Serie
SC 13G Filing — SC 13G · Oct 7, 2024
AH Capital Management Files 13D for BioAge Labs — SC 13D · Oct 4, 2024 Risk: medium
On October 4, 2024, AH Capital Management, L.L.C. and its affiliates, including AH Bio Fund I, L.P., filed a Schedule 13D regarding their holdings in BioAge Lab
Sofinnova Group Discloses Stake in BioAge Labs — SC 13D · Sep 30, 2024 Risk: medium
On September 30, 2024, Sofinnova Venture Partners XI, L.P. and its group members, including Dr. James I. Healy and Dr. Maha Katabi, reported beneficial ownershi
BioAge Labs Files 8-K: Material Agreement & Equity Sales — 8-K · Sep 27, 2024 Risk: medium
On September 25, 2024, BioAge Labs, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
BioAge Labs Files S-1/A Amendment for IPO — S-1/A · Sep 25, 2024 Risk: medium
BioAge Labs, Inc. filed an S-1/A amendment on September 25, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register
BioAge Labs Files S-1/A for IPO — S-1/A · Sep 18, 2024 Risk: medium
BioAge Labs, Inc. filed an S-1/A amendment on September 18, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register
BioAge Labs Files S-1 for Public Offering — S-1 · Sep 3, 2024 Risk: medium
BioAge Labs, Inc., a Delaware-based company in the pharmaceutical preparations sector, filed an S-1 registration statement on September 3, 2024. The company, lo

Risk Profile

Risk Assessment: Of BIOA's 16 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bioage Labs, INC.'s most recent 10-K filing (Mar 24, 2026):

Revenue: $0
Net Income: $-XX.X million
EPS: $X.XX
Debt-to-Equity: N/A
Cash Position: $XX.X million
Operating Margin: N/A
Total Assets: $XX.X million
Total Debt: $0

Key Executives

Paul D. Rubin
0001210905
Kristen Fortney
Eric Morgen
Dov Goldstein
Paul Rubin
Ann Neale
Marc Andreessen
Benjamin Horowitz
Dr. James I. Healy
Dr. Maha Katabi
Nathalie Auber
Kristen Fortney, Ph.D.

Industry Context

BioAge Labs operates in the highly competitive biopharmaceutical sector, focusing on the intersection of aging biology and metabolic diseases. The company's strategy leverages human datasets to identify novel targets, with BGE-102, an NLRP3 inhibitor, as its lead candidate. The market for obesity and cardiovascular disease treatments is substantial, with projected global markets for GLP-1R agonists reaching $150 billion by 2031, indicating significant commercial opportunity. However, the development landscape is crowded with both established pharmaceutical giants and emerging biotech firms, necessitating strong differentiation and clinical validation.

Top Tags

sec-filing (4) · biotech (4) · Biotechnology (3) · ipo (3) · Clinical Trials (2) · Aging Research (2) · Drug Development (2) · 10-Q (2) · pharmaceutical (2) · insider-filing (1)

Key Numbers

Form Type: 144 — Indicates a proposed sale of securities
CIK: 0001709941 — BioAge Labs, Inc. identifier
Aggregate market value of common equity held by non-affiliates: $112.7 million — as of June 30, 2025, indicating company size
Shares of Common Stock outstanding: 44,379,753 — as of March 19, 2026
Median reduction in hsCRP for BGE-102: 86% — at Day 14 in obese participants with elevated cardiovascular risk
Participants achieving hsCRP levels below 2 mg/L: 93% — after BGE-102 treatment, associated with 25% reduction in MACE
Projected global market for GLP-1R agonists: $150 billion — by 2031, highlighting market opportunity for obesity treatments
Patients affected by Diabetic Macular Edema (DME): 1 million — in the United States, a target indication for BGE-102
DME patients refractory to anti-VEGF therapy: 45% — indicating significant unmet need for new treatments
Net Loss (Q3 2025): $20.17M — Improved from $23.41M in Q3 2024
Net Loss (9 Months 2025): $54.66M — Increased from $49.98M in 9 Months 2024
Collaboration Revenue (9 Months 2025): $5.92M — First-time revenue, up from $0 in 9 Months 2024
Research and Development Expenses (9 Months 2025): $49.47M — Increased from $39.81M in 9 Months 2024
General and Administrative Expenses (9 Months 2025): $20.81M — Increased from $13.02M in 9 Months 2024
Cash, Cash Equivalents, and Marketable Securities (Sept 30, 2025): $295.9M — Sufficient to fund operations for at least one year

Related Companies

LLY · NVS · BGLD · SVB · BAGE

Frequently Asked Questions

What are the latest SEC filings for Bioage Labs, INC. (BIOA)?

Bioage Labs, INC. has 21 recent SEC filings from Sep 2024 to Apr 2026, including 5 8-K, 4 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BIOA filings?

Across 21 filings, the sentiment breakdown is: 18 neutral, 3 mixed. The dominant sentiment is neutral.

Where can I find Bioage Labs, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Bioage Labs, INC. (BIOA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Bioage Labs, INC.?

Key financial highlights from Bioage Labs, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BIOA?

The investment thesis for BIOA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Bioage Labs, INC.?

Key executives identified across Bioage Labs, INC.'s filings include Paul D. Rubin, 0001210905, Kristen Fortney, Eric Morgen, Dov Goldstein and 8 others.

What are the main risk factors for Bioage Labs, INC. stock?

Of BIOA's 16 assessed filings, 3 were flagged high-risk, 9 medium-risk, and 4 low-risk.

What are recent predictions and forward guidance from Bioage Labs, INC.?

Forward guidance and predictions for Bioage Labs, INC. are extracted from SEC filings as they are enriched.